Technology

Our pioneering approach seamlessly integrates advanced antibody discovery, AxcynCYS™ site-specific conjugation, and a proprietary payload, AxcynDOT™ with a different mechanism of action with the potential of overcoming drug resistance encountered with current ADC payloads like DM1, MMAE, and DXd.

AxcynCYS™

AxcynCYS™ technology allows reproducible site-specific conjugation to achieve a highly homogeneous (>95%) ADC product (DAR value between 2 to 8), by introducing cysteine mutations at specific sites on the antibody.
The systematic combination of pairs of cysteine mutations identified the optimal combination for DAR4 product to reproducibly provide the highest HIC purity.
AxcynDOT™ is a proprietary payload developed based on the FDA-approved drug, Trabectedin. It is chemically modified by installing a linker handle, increasing potency across multiple cell-lines , and improving pharmacokinetic properties to the parent drug.

AxcynDOT™